Lingqi Meng, Han Jin, Burak Yulug, Ozlem Altay, Xiangyu Li, Lutfu Hanoglu, Seyda Cankaya, Ebru Coskun, Ezgi Idil, Rahim Nogaylar, Ahmet Ozsimsek, Saeed Shoaie, Hasan Turkez, Jens Nielsen, Cheng Zhang, Jan Borén, Mathias Uhlén, Adil Mardinoglu
{"title":"多组学分析揭示了阿尔茨海默病严重程度的关键因素。","authors":"Lingqi Meng, Han Jin, Burak Yulug, Ozlem Altay, Xiangyu Li, Lutfu Hanoglu, Seyda Cankaya, Ebru Coskun, Ezgi Idil, Rahim Nogaylar, Ahmet Ozsimsek, Saeed Shoaie, Hasan Turkez, Jens Nielsen, Cheng Zhang, Jan Borén, Mathias Uhlén, Adil Mardinoglu","doi":"10.1186/s13195-024-01578-6","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a debilitating neurodegenerative disorder with a global impact, yet its pathogenesis remains poorly understood. While age, metabolic abnormalities, and accumulation of neurotoxic substances are potential risk factors for AD, their effects are confounded by other factors. To address this challenge, we first utilized multi-omics data from 87 well phenotyped AD patients and generated plasma proteomics and metabolomics data, as well as gut and saliva metagenomics data to investigate the molecular-level alterations accounting the host-microbiome interactions. Second, we analyzed individual omics data and identified the key parameters involved in the severity of the dementia in AD patients. Next, we employed Artificial Intelligence (AI) based models to predict AD severity based on the significantly altered features identified in each omics analysis. Based on our integrative analysis, we found the clinical relevance of plasma proteins, including SKAP1 and NEFL, plasma metabolites including homovanillate and glutamate, and Paraprevotella clara in gut microbiome in predicting the AD severity. Finally, we validated the predictive power of our AI based models by generating additional multi-omics data from the same group of AD patients by following up for 3 months. Hence, we observed that these results may have important implications for the development of potential diagnostic and therapeutic approaches for AD patients.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"213"},"PeriodicalIF":7.9000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448018/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer's disease.\",\"authors\":\"Lingqi Meng, Han Jin, Burak Yulug, Ozlem Altay, Xiangyu Li, Lutfu Hanoglu, Seyda Cankaya, Ebru Coskun, Ezgi Idil, Rahim Nogaylar, Ahmet Ozsimsek, Saeed Shoaie, Hasan Turkez, Jens Nielsen, Cheng Zhang, Jan Borén, Mathias Uhlén, Adil Mardinoglu\",\"doi\":\"10.1186/s13195-024-01578-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Alzheimer's disease (AD) is a debilitating neurodegenerative disorder with a global impact, yet its pathogenesis remains poorly understood. While age, metabolic abnormalities, and accumulation of neurotoxic substances are potential risk factors for AD, their effects are confounded by other factors. To address this challenge, we first utilized multi-omics data from 87 well phenotyped AD patients and generated plasma proteomics and metabolomics data, as well as gut and saliva metagenomics data to investigate the molecular-level alterations accounting the host-microbiome interactions. Second, we analyzed individual omics data and identified the key parameters involved in the severity of the dementia in AD patients. Next, we employed Artificial Intelligence (AI) based models to predict AD severity based on the significantly altered features identified in each omics analysis. Based on our integrative analysis, we found the clinical relevance of plasma proteins, including SKAP1 and NEFL, plasma metabolites including homovanillate and glutamate, and Paraprevotella clara in gut microbiome in predicting the AD severity. Finally, we validated the predictive power of our AI based models by generating additional multi-omics data from the same group of AD patients by following up for 3 months. Hence, we observed that these results may have important implications for the development of potential diagnostic and therapeutic approaches for AD patients.</p>\",\"PeriodicalId\":7516,\"journal\":{\"name\":\"Alzheimer's Research & Therapy\",\"volume\":\"16 1\",\"pages\":\"213\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2024-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448018/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's Research & Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13195-024-01578-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-024-01578-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
阿尔茨海默病(AD)是一种影响全球的令人衰弱的神经退行性疾病,但人们对其发病机制仍然知之甚少。虽然年龄、代谢异常和神经毒性物质的积累是导致阿尔茨海默病的潜在风险因素,但它们的影响受到其他因素的干扰。为了应对这一挑战,我们首先利用了 87 名表型良好的 AD 患者的多组学数据,并生成了血浆蛋白质组学和代谢组学数据,以及肠道和唾液元基因组学数据,以研究宿主与微生物组相互作用的分子级改变。其次,我们分析了个体 omics 数据,并确定了与 AD 患者痴呆症严重程度相关的关键参数。接下来,我们采用基于人工智能(AI)的模型,根据每项全局组学分析中发现的显著改变特征来预测AD的严重程度。在综合分析的基础上,我们发现血浆蛋白(包括 SKAP1 和 NEFL)、血浆代谢物(包括同羟戊酸盐和谷氨酸盐)以及肠道微生物组中的 Paraprevotella clara 对预测 AD 的严重程度具有临床意义。最后,我们通过对同一组 AD 患者进行 3 个月的随访,生成了额外的多组学数据,从而验证了我们基于人工智能的模型的预测能力。因此,我们认为这些结果可能对开发潜在的 AD 患者诊断和治疗方法具有重要意义。
Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer's disease.
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder with a global impact, yet its pathogenesis remains poorly understood. While age, metabolic abnormalities, and accumulation of neurotoxic substances are potential risk factors for AD, their effects are confounded by other factors. To address this challenge, we first utilized multi-omics data from 87 well phenotyped AD patients and generated plasma proteomics and metabolomics data, as well as gut and saliva metagenomics data to investigate the molecular-level alterations accounting the host-microbiome interactions. Second, we analyzed individual omics data and identified the key parameters involved in the severity of the dementia in AD patients. Next, we employed Artificial Intelligence (AI) based models to predict AD severity based on the significantly altered features identified in each omics analysis. Based on our integrative analysis, we found the clinical relevance of plasma proteins, including SKAP1 and NEFL, plasma metabolites including homovanillate and glutamate, and Paraprevotella clara in gut microbiome in predicting the AD severity. Finally, we validated the predictive power of our AI based models by generating additional multi-omics data from the same group of AD patients by following up for 3 months. Hence, we observed that these results may have important implications for the development of potential diagnostic and therapeutic approaches for AD patients.
期刊介绍:
Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.